Deal Watch Asia Focus: Pfenex Licenses Asian Rights To Forteo Copy To NT Pharma Group
Executive Summary
Otsuka obtains Japanese rights to two cancer gene therapy candidates from Takara. GlaxoSmithKline extends its protein degradation collaboration with Kymera.
You may also be interested in...
Sanofi Nabs Kymera IRAK4 Protein Degrader As It Continues To Build In I&I
Kymera will receive $150m upfront from Sanofi in a deal the big pharma views as an opportunity to develop a breakthrough oral drug for atopic dermatitis and other conditions.
Vertex Targeting Protein Degradation In $1bn Kymera Deal
Vertex and Kymera will use insights into the ubiquitin-proteasome pathway, for sending unwanted proteins off to recycling, to discover new drug candidates.
World First Korea Darbepoetin Biosimilar Approval To Speed CKD's Global Entry?
With a global first marketing authorization for its darbepoetin biosimilar in South Korea, Chong Kun Dang aims to speed up the product’s entry into the Japanese and other international markets and progress clinical rials with other biosimilars and novel biologics.